



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

Date OCT 25 1985

NDA No. 16-331

Roche Dermatology
340 Kingsland St.
Nutley, N.J. 07110-1109

Attention: Spnia M. Haley

Dear Sir/Madam:

We acknowledge receipt of your supplemental application for the following:

Name of Drug: Efudex Cream and Topical Solutions.

NDA Number: 16-331

Supplement Number: S-023

Date of Supplement: October 12, 1985

Date of Receipt: October 13, 1985

All communications concerning this NDA should be addressed as follows:

Center for Drugs and Biologics, HFN-815
Attention: Document Control Room 12B-30
5600 Fishers Lane
Rockville, MD 20857

Supervisory Consumer Safety Officer
Division of Anti-Infective Drug Products
Center for Drugs and Biologics

cc:
NDA File
HFN-815 File
CSO File

BEST POSSIBLE COPY

FORM FDA 3217d (7/84)

U.S. GOVERNMENT PRINTING OFFICE-1934-450-521/7435

NDA 16-831/S-028

Sonia M. Haley
Senior Regulatory Specialist
Drug Regulatory Affairs
Hoffmann-La Roche
Nutley, NJ 07110

Dear Ms. Haley:

Please refer to your supplemental New Drug Application dated October 12, 1988 submitted pursuant to section 505(b) of the Federal Food, Drug, and Cosmetic Act for Efudex (fluorouracil) Topical Solution.

The supplemental application provides for the Sisseln, Switzerland facility of Hoffmann-La Roche to be an alternate source of the new drug substance fluorouracil.

We have completed the review of this supplemental application and it is approved. Our letter of July 29, 1970 detailed the conditions relating to the approval of this application.

Sincerely yours,

[Signature]

Armand R. Casola, Ph.D.
Supervisory Chemist
Division of Anti-Infective
Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

cc: Orig NDA
HFD-82
~~HFD-520~~
HFD-520/MO-Sanders
HFD-520/SRT
HFD-520/Gavrilovich
HFD-520/Pharm-Browder
HFD-520/ARCasola
HFD-520/Chem-MAJarski: gm 11/28/88
HFD-520/CSO-Bostwick
R/D initialed by ARCasola: 11/28/88
Approved
1227c

[Signature] 11/28/88

[Signature] 11/29/88

NDA SUPPLEMENT REVIEW		
<u>CHEMIST'S REVIEW #1</u>	1. ORGANIZATION DAIDP	2. NDA NUMBER 16-831
3. NAME AND ADDRESS OF APPLICANT (CITY AND STATE) Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley, NJ 07001		4. APPROVED 7-29-70
		5. SUPPLEMENT(s) NUMBER(s) DATE(s)
6. NAME OF DRUG Efudex	7. NONPROPRIETARY NAME fluorouracil	S-028 10-12-88
8. SUPPLEMENT(s) PROVIDES FOR: The Sisseln, Switzerland facility of Hoffmann-La Roche to be an alternate source of the new drug substance fluorouracil. Special Supplement - Changes Being Effectuated		9. AMENDMENTS AND OTHER (Reports, etc.) DATES None
10. PHARMACOLOGICAL CATEGORY antineoplastic	11. HOW DISPENSED Rx	12. RELATED IND/NDA/DMF(s)
13. DOSAGE FORM(s) Topical Solution	14. POTENCY(ies) 2% and 5%	
15. CHEMICAL NAME AND STRUCTURE USP		16. RECORDS AND REPORTS CURRENT: YES REVIEWED: YES
17. COMMENTS On December 5, 1986 Type I [redacted] was submitted to provide for a Hoffman-La Roche facility located in Sisseln, Switzerland. This facility will produce fluorouracil for use in Efudex cream and topical solutions. The process for synthesis is the same as used at the Basle facility (re: S-014, approved 11-21-78) and the product meets the same specifications as that produced at the Basle plant. When remaining supplies of fluorouracil produced at the Basle facility are exhausted, manufacturing will continue using fluorouracil produced at the Sisseln plant. At that time representative lots of both cream and solution will be placed in the stability program. (Note: such a lot of cream is already in the Roche stability program) The Sisseln facility has been licensed (copy included with the supplement) by the Swiss authorities. There is a memorandum of understanding between the U.S. and Swiss governments that inspections by Swiss authorities are acceptable in lieu of U.S. inspectors. Thus the facility is considered acceptable. Since the applicant certifies the synthesis is the same as previously approved for the Basle facility, manufacturing and control information is considered acceptable.		
18. CONCLUSIONS AND RECOMMENDATIONS Approve S-028. Approval letter to issue. cc: ORIG. NDA HFD-502/Ckumkumian HFD-520 HFD-520/ARCasola, HFD-520/Chem-MAJarski HFD-520/MO-Sanders, HFD-520/Pharm-Browder HFD-520/CSO-Bostwick 0050n R/D init. by ARCasola, Ph.D		
19. REVIEWER		
NAME Mary Ann Jarski	SIGNATURE /S/ 11/28/88 /S/ 11/23/88	DATE COMPLETED November 23, 1988